BIOMAT Database Logo BIOMAT Database Logo

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. 1995

R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
Department of Medicine, University of California, San Diego.

Ro 24-7429, a Tat antagonist, dosed at 75, 150, or 300 mg/day, was compared with nucleoside analogue (zidovudine or didanosine) for 12 weeks in 96 human immunodeficiency virus (HIV)-infected patients to assess safety and activity. The primary adverse effect of Ro 24-7429 was rash, which necessitated treatment discontinuation in 6 of 71 patients. Nucleoside analogue treatment produced an average increase in CD4 cell count of 28 cells/mm3 at week 8 versus a decrease of 27 cells/mm3 in recipients of Ro 24-7429 (P < .001). Serum HIV p24 antigen levels decreased by an average of 111 pg/mL in nucleoside recipients at week 8 compared with an increase of 41 pg/mL in recipients of Ro 24-7429 (P = .007). Nucleoside-treated patients had a mean 0.66 log10 reduction in infectious peripheral blood mononuclear cells, while Ro 24-7429 recipients had a mean 0.02 log10 reduction (P = .02). No dose-response relationships were observed in the Ro 24-7429 groups. In this study, Ro 24-7429 treatment showed no evidence of antiviral activity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
February 1998, Pediatrics,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
March 1995, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.
June 1999, Antimicrobial agents and chemotherapy,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.
May 1998, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
August 1992, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
April 1996, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429.
September 1994, Journal of leukocyte biology,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
March 1995, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
September 1997, The New England journal of medicine,
R H Haubrich, and C Flexner, and M M Lederman, and M Hirsch, and C P Pettinelli, and R Ginsberg, and P Lietman, and F M Hamzeh, and S A Spector, and D D Richman
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
May 1997, The Journal of infectious diseases,
Copied contents to your clipboard!